Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival

Xu,Linping; Long,Jianping; Wang,Peng; Liu,Kangdong; Mai,Ling; Guo,Yongjun

doi:10.3892/ol.2015.3201

Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival

Authors:
- Linping Xu
- Jianping Long
- Peng Wang
- Kangdong Liu
- Ling Mai
- Yongjun Guo
View Affiliations

Affiliations: Department of Scientific Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Breast Surgery, Maternity and Child-Care Hospital of Gansu Province, Lanzhou, Gansu 730050, P.R. China, Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: May 12, 2015 https://doi.org/10.3892/ol.2015.3201
Pages: 485-491

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ornithine decarboxylase (ODC) is a significant rate‑limiting enzyme in polyamine synthesis, required for normal cell growth, and is highly expressed in various malignancies, including colorectal and breast cancer. In the present study, the associations between the ODC G316A single nucleotide polymorphism (SNP) and breast cancer‑specific survival were investigated. In addition, the functional effects of this SNP were examined in the MCF‑7 human breast cancer cell line. The present study recruited 300 stage I‑III breast cancer cases, which were diagnosed at the Affiliated Cancer Hospital of Zhengzhou University (Zhengzhou, China) between 2002 and 2003, with follow‑up visits conducted until May 2013. ODC G316A was genotyped (ODC GG vs. ODC AG/AA) in the 300 cases and the association of the genotypes with cancer‑specific survival was analyzed. In the MCF‑7 cell line, the ODC allele‑specific binding of E‑box transcription factors was determined using western blot and chromatin immunoprecipitation assays. Survival differences were observed between the two genotypes: Compared with the ODC GG genotype, patients with ODC GA/AA exhibited significantly higher survival rates (P<0.05). In cultured cells, the ODC SNP, which is flanked by two E‑boxes, appeared to predict ODC promoter activity. Furthermore, the E‑box activator c‑MYC and repressor MAX interactor 1 were found to preferentially bind to ODC minor A‑alleles compared with major G‑alleles, in cultured MCF‑7 cells. In conclusion, the results of the current study suggest that the regulation of ODC may affect survival in breast cancer patients and indicate a model in which the ODC SNP may be protective for breast adenoma recurrence and detrimental for survival following a diagnosis of breast cancer.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gerner EW and Meyskens FL Jr: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 4:781–792. 2004. View Article : Google Scholar : PubMed/NCBI
3	Wallace HM: The physiological role of the polyamines. Eur J Clin Invest. 30:1–3. 2000. View Article : Google Scholar : PubMed/NCBI
4	Babbar N, Ignatenko NA, Casero RA Jr and Gerner EW: Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 278:47762–47775. 2003. View Article : Google Scholar : PubMed/NCBI
5	Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A and Suzuki F: Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res. 50:4131–4138. 1990.PubMed/NCBI
6	Gödderz D, Schäfer E, Palanimurugan R and Dohmen RJ: The N-terminal unstructured domain of yeast ODC functions as a transplantable and replaceable ubiquitin-independent degron. J Mol Biol. 407:354–367. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chen Y, Megosh LC, Gilmour SK, Sawicki JA and OBrien TG: K6/ODC transgenic mice as a sensitive model for carcinogen identification. Toxicol Lett. 116:27–35. 2000. View Article : Google Scholar : PubMed/NCBI
8	Young L, Salomon R, Au W, Allan C, Russell P and Dong Q: Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. J Histochem Cytochem. 54:223–229. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lan L, Trempus C and Gilmour SK: Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res. 60:5696–5703. 2000.PubMed/NCBI
10	Guo Y, Cleveland JL and OBrien TG: Haploinsufficiency for odc modifies mouse skin tumor susceptibility. Cancer Res. 65:1146–1149. 2005. View Article : Google Scholar : PubMed/NCBI
11	Grinberg AV, Hu CD and Kerppola TK: Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol Cell Biol. 24:4294–4308. 2004. View Article : Google Scholar : PubMed/NCBI
12	Walhout AJ, Gubbels JM, Bernards R, van der Vliet PC and Timmers HT: c-Myc/Max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (ODC) gene. Nucleic Acids Res. 25:1493–1501. 1997. View Article : Google Scholar : PubMed/NCBI
13	Funakoshi-Tago M, Sumi K, Kasahara T and Tago K: Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. PLoS One. 8:e528442013. View Article : Google Scholar : PubMed/NCBI
14	Guo Y, Harris RB, Rosson D, Boorman D and OBrien TG: Functional analysis of human ornithine decarboxylase alleles. Cancer Res. 60:6314–6317. 2000.PubMed/NCBI
15	Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ and Houlston RS: Members of the UKCAP Consortium: Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res. 14:2303–2309. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zell JA, Ziogas A, Ignatenko N, et al: Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res. 15:6208–6216. 2009. View Article : Google Scholar : PubMed/NCBI
17	Theriault RL, Carlson RW, Allred C, et al: National Comprehensive Cancer Network: Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 11:753–760. 2013.PubMed/NCBI
18	Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
19	Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 20:3628–3636. 2002. View Article : Google Scholar : PubMed/NCBI
20	Leen S, Steven VL, Marie DA, et al: Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer. Patholog Res Int. 2014:3726532014.PubMed/NCBI
21	Casero RA and Pegg AE: Polyamine catabolism and disease. Biochem J. 421:323–338. 2009. View Article : Google Scholar : PubMed/NCBI
22	Thomas T and Thomas TJ: Polyamine metabolism and cancer. J Cell Mol Med. 7:113–126. 2003. View Article : Google Scholar : PubMed/NCBI
23	Wallace HM and Fraser AV: Inhibitors of polyamine metabolism: review article. Amino Acids. 26:353–365. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wallace HM and Fraser AV: Inhibitors of polyamine metabolism: review article. Amino Acids. 26:353–365. 2004. View Article : Google Scholar : PubMed/NCBI
25	Levin VA, Uhm JH, Jaeckle KA, et al: Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 6:3878–3884. 2000.PubMed/NCBI
26	Deng X and Pei D: Ornithine decarboxylase and glutamate decarboxylase 65 as prognostic markers of gallbladder malignancy: a clinicopathological study in benign and malignant lesions of the gallbladder. Mol Med Rep. 7:413–418. 2013.PubMed/NCBI
27	Wilson SM, Hawel L III, Pastorian KE and Byus CV: A stable, inducible, dose-responsive ODC overexpression system in human cell lines. Biochim Biophys Acta. 1732:103–110. 2005. View Article : Google Scholar : PubMed/NCBI
28	Love RR, Astrow SH, Cheeks AM and Havighurst TC: Ornithine decarboxylase (ODC) as a prognostic factor in operable breast cancer. Breast Cancer Res Treat. 79:329–334. 2003. View Article : Google Scholar : PubMed/NCBI
29	Luqman S: Ornithine decarboxylase: a promising and exploratory candidate target for natural products in cancer chemoprevention. Asian Pac J Cancer Prev. 13:2425–2427. 2012. View Article : Google Scholar : PubMed/NCBI
30	Martinez ME, OBrien TG, Fultz KE, et al: Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA. 100:7859–7864. 2003. View Article : Google Scholar : PubMed/NCBI
31	Brown I, Halliday S, Greig H, et al: Genetic polymorphism in ornithine decarboxylase and risk of breast cancer. Fam Cancer. 8:307–311. 2009. View Article : Google Scholar : PubMed/NCBI
32	Xu LP, Sun Y, Li W, Mai L, Guo YJ and Fan QX: MYC and MXI1 protein expression: potential prognostic significance in women with breast cancer in China. Oncol Res Treat. 37:118–123. 2014. View Article : Google Scholar : PubMed/NCBI